Company: TBPH
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001104659-25-110382
Chunk: 7

Company: Theravance Biopharma, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part II, Item 5
Chunk 7
---
ITEM 5.   OTHER INFORMATION

​

Trading Plans

During the three months ended September 30, 2025, none of our Section 16 officers or directors adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, except as described in the table below:

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Rule 10b5-1 ​​​​​​​Duration of Trading ​Trading Arrangement? Number of OrdinaryName and Title    Action    Date   Arrangement  (Y / N) (1) Shares to be Sold​Rhonda F. Farnum,Chief Business Officer and Senior Vice President,Commercial & Medical Affairs​​​​​Adoption​September 3, 2025​September 3, 2025 - December 3, 2026​Y​Up to 88,762(1)Denotes whether the trading plan is intended to satisfy the affirmative defense Rule 10b5-1(c) of the Exchange Act. 

​

​

​

​

​

​

​